Bevacizumab Plus ADT May Up Survival in Recurrent Prostate Cancer

Adding bevacizumab to androgen deprivation therapy resulted in improved relapse-free survival in patients with hormone-sensitive prostate cancer.
Adding bevacizumab to androgen deprivation therapy resulted in improved relapse-free survival in patients with hormone-sensitive prostate cancer.

Adding bevacizumab to androgen deprivation therapy (ADT) resulted in improved relapse-free survival in patients with hormone-sensitive prostate cancer, a study published in the Journal of Clinical Oncology has shown.

ADT is a typical treatment strategy for patients with recurrent prostate cancer who have received local therapy. Researchers sought to investigate efficacy and toxicity of short-course ADT with or without bevacizumab, a vascular endothelial growth factor A (VEGF-A) inhibitor, in men with hormone-sensitive prostate cancer.

For the phase 2 study, researchers enrolled 102 patients who had an increasing prostate-specific antigen (PSA) of no more than 50 ng/mL and a PSA level that has doubled in less than 18 months. Patients were eligible if they had either no metastases or low burden, asymptomatic metastases.

Continue Reading Below

Participants were randomly assigned 2:1 to receive bicalutamide as ADT plus bevacizumab or ADT alone for 6 months.

Results showed that patients receiving ADT plus bevacizumab had a relapse-free survival of 13.3 months compared with 10.2 months for ADT alone (HR, 0.47; 95% CI, 0.29 - 0.77; P = .002). Relapse was defined as a PSA of more than 0.2 ng/mL for prostatectomy patients or PSA of more than 2.0 ng/mL for primary radiation therapy patients.

In terms of safety, 36% of patients who received ADT plus bevacizumab developed hypertension.

Although these findings are encouraging, long-term follow-up is necessary to determine whether some patients achieve a durable PSA response are able to discontinue ADT for prolonged periods.

Source

  1. McKay RR, Zurita AJ, Werner L, et al. A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy [published online ahead of print April 4, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.63.3154.
Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign up for free e-Newsletters